Friday, July 19, 2019 UTC
Recognized by industry leaders for extensive coverage on African Asset Management

AGF 2019 Events - October 24th, Radisson Blu Hotel, Johannesburg

AGF Forum: PE Fund Operations

The 2019 AGF Forum will assemble cutting-edge thinkers, management of leading Private Equity Firms (CFOs, COOs, CTOs), and Asset Managers to discuss the major developments that affect private investment fund operations.

8AM - 5PM

More Info

AGF Service Providers Awards

The 4th edition of the prestigious Awards has opened for entries in the build up to the Awards night in Johannesburg, South Africa. Deadline for submissions: September 1st; judging period is from July 2018 to June 2019.

7PM - 11PM

Submissions Open
News > Private Equity > Exits

Abraaj and Proparco exit Tunisian pharma company to Blakeney and others

Africa Global Funds
Jan. 4, 2016, midnight
565

Word count: 445

Abraaj and Proparco have exited 83% of their combined stake in Tunisian pharmaceutical company Unité de fabrication de medicaments to a consortium of investors including Washington-based SQM, Blakeney Asset Management, the Tunisian-Kuwaiti Consortium of Development (CTKD), and two local investors.

Receive ONE magazine and TWO locked articles of your choice for FREE when you register an account
Share:

Abraaj and Proparco have exited 83% of their combined stake in Tunisian pharmaceutical company Unité de fabrication de medicaments to a consortium of investors including Washington-based SQM, Blakeney Asset Management, the Tunisian-Kuwaiti Consortium of Development (CTKD), and two local investors.

Established in 1989 by Ridha Charfeddine, Unimed is the second largest local pharmaceutical company in Tunisia, specializing in sterile dosage forms such as liquid and powder injectables, intravenous (IV) solutions and a range of ophthalmic products.

Unimed manufactures for global partners such as Pfizer and Mylan, and is the first company in Tunisia to be AFFSAP-certified.

Abraaj, through one of its Funds, invested in Unimed in 2011.

Since the start of its investment, Abraaj, alongside Unimed’s leadership team, increased the company’s revenue year-on-year.

Ahmed Badreldin, Partner and Regional Head for Middle East and North Africa at The Abraaj Group, said: “Our investment in Unimed over the past four years has helped cement the company’s position as a leading pharmaceutical manufacturer in North Africa.”

“The healthcare market, a critical sector in North Africa, is still underserved and growing rapidly, driven by a rising middle class with an increasing propensity to invest in quality healthcare. We believe Unimed is now well positioned to capitalize on the substantial growth opportunities that it will have as a listed company on the Tunis stock exchange and as it expands across the African continent and the wider Middle East region,” he added.

Unimed currently holds 329 marketing authorizations, including 97 obtained over the last two years.

The company has also increasingly adopted an export-focused strategy which resulted in 41.5% of total sales in 2014 being exported to over 17 countries in North Africa, West Africa, Europe and the Middle East.

Abraaj’s financial and operational support has enabled Unimed to expand its regional footprint, upgrade manufacturing equipment and enhance its corporate governance and financial reporting mechanisms.

Unimed places a strong focus on workforce development by implementing training and development programs for its employees.

Almost half of Unimed’s workforce is made up of women, 25.8% higher than the average female to male ratio in the Tunisian labor force.

Ridha Charfeddine, Founder at Unimed, said: “Abraaj has played an instrumental role in helping us provide trusted healthcare solutions across North Africa and increase our exports to regional markets. With our new partners on board, we look forward to working together in the next growth chapter of our business.”

Since 2003, Abraaj has deployed nearly $1bn globally across the healthcare spectrum in growth markets, including healthcare delivery and services, diagnostics centers and pharmaceuticals.

Abraaj has four investments in Tunisia including the North Africa Hospital Holdings Group, a healthcare platform to enhance the quality and accessibility of healthcare in Egypt and Tunisia, and L’Accumulateur Tunisien ASSAD, a leading battery manufacturer.

Registration Login
Sign in with social account
or
Lost your Password?
Registration Login
Sign in with social account
or
Registration Login
Registration